SandboxAQ Makes AQPotency Available for Drug Discovery
SandboxAQ announced in a press release the general availability of AQPotency, a Large Quantitative Model for drug discovery that is available on Claude through Model Context Protocol. The model predicts how strongly candidate molecules are likely to act on disease targets without requiring a solved protein structure.
AQPotency ranks molecule and target pairs in seconds on ordinary computing hardware. The company said the service can cost as little as $1 per 1,000 comparisons and returns confidence information with each prediction.
The system can also start with one molecule and scan a panel of proteins to rank likely targets. SandboxAQ said the model has been used in eight customer programs with experimental validation.
AQPotency is available through Claude and SandboxAQ's website. Availability on the Marketplace from Google Cloud is planned to follow.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 12 ADLM to Brief Congress on Healthcare AI Policy Oct 12 Function Brings Lab Results to Google Health App Oct 12 DeepSight Technology Adds Scott Huennekens to Board Oct 12 Flo Health Partners With Google Health on Wearables and Women's Health AI Oct 12 Immorta Bio completes preclinical studies of AI designed senolytic peptideLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Apodex Offers Free AI Drug Research Services
Lunai Bioworks Tests AI Chemical Risk Screening Model
Inductive Bio launches Beacon-2 to predict human drug doses
Novo Nordisk Partners With Anthropic on Drug Research
Quotient Sciences and Acesion Apply AI to Atrial Fibrillation Drugs
Daily AI Brief: the AI news that matters, in your inbox.